亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Risk Factors and Characteristics of CRS in CAR-T Treatment

医学 氟达拉滨 不利影响 入射(几何) 不良事件通用术语标准 汽车T细胞治疗 内科学 多发性骨髓瘤 来那度胺 环磷酰胺 外科 癌症 嵌合抗原受体 化疗 免疫疗法 物理 光学
作者
Zhiling Yan,Huan-Xin Zhang,Ying Wang,Jiang Cao,Jianlin Qiao,Deipeng Li,Bin Pan,Qingyun Wu,Zhenyu Li,Kailin Xu
出处
期刊:Blood [Elsevier BV]
卷期号:134 (Supplement_1): 4462-4462 被引量:1
标识
DOI:10.1182/blood-2019-129777
摘要

Background and objective Clinical trials have confirmed that CAR-T treatment has become one of the important treatments for many relapse and refractory hematological tumors. CRS is a high incidence of adverse events in CAR-T treatment. A deeply understanding of the characteristics and related risk factors of CRS is important for the effective management of CRS. The characteristics and risk factors of CRS occurred in 142 patients during CAR-T treatment were analyzed in detail to provide a direct and reliable basis for clinicians to diagnose and predict CRS. Patients and Methods We collected 142 patients with different hematologic malignancies who underwent CAR-T treatment from January 2015 to December 2018. All patients were screened according to the inclusion and exclusion criteria at the time of trial design. Patients received Fludarabine and cyclophosphamide to remove T cells before infusion of CAR-T. Infused CAR-T cells include anti-CD19 CAR-T, anti-BCMA CAR-T and anti-CD20 CAR-T. Glucocorticoids were not used to prevent allergic reactions prior to infusion. Adverse events were assessed using the CRS evaluation criteria proposed by Lee et al. and the Common Terminology Criteria for Adverse Events (CTCAEs, version 4.0) criteria. Results: 1.General characteristics of patients and CRS Of all patients, 87 (61.3%) were male and 55 (38.7%) were female; the median age was 45 (IRQ = 24-59). The incidence of CRS in ALL, lymphoma and myeloma were: 82%, 90% and 90%, respectively. Fever is the main first symptom of CRS. The median time to onset of fever is 3 days for ALL (IRQ 0-7 days), 1 day for lymphoma (IRQ 0-5 days), and 8.5 days for MM (1.75-12.75 days). There was a statistically significant difference between MM and ALL (p=0.0044) or MM and lymphoma (p=0.0002). The duration of fever was different between CRS grade 1-2 and grade 3-5 (P=0.007), but there was no difference between ALL, lymphoma, and MM [3 (0-7 days) vs 5 (3-8 days) vs 4(3-8 days)]. Levels of serum ferritin, IL-6, and CRP were consistent with CRS, but there was no significant difference in different time points after CAR-T infusion except for IL-6 levels of ALL patients between days 7 and 10. However, the peak concentration of ferritin, IL-6, and CRP is different from the baseline. 2.General risk factors for CRS In the univariate analysis, the maximum concentration of serum IL-6 (p=0.000) and CRP (p=0.001) were different between CRS3-5, CRS1-2, and patients without CRS. For further analysis, the IL-6 was statistically different between CRS3-5 and CRS1-2 (p=0.03), CRS3-5 and Non-CRS (p=0.00), or CRS1-2 and Non-CRS (p=0.00). The CRP was statistically different between CRS3-5 and Non-CRS (p=0.00), CRS1-2 and Non-CRS (p=0.01). There were no differences in age, gender, pre-transplantation, type of disease, dose of CAR-T cells, and costimulatory molecules. In multivariate analysis, disease (ALL vs MM (p=0.043), ALL vs MM (p=0.021)), costimulatory molecules (p=0.022), peak concentration of IL-6 (p=0.000) and CRP (p=0.001) are independent risk factors. 3.Specific risk factors For ALL patients, in the univariate analysis, the number of lymphoblasts in the bone marrow before FC deplete lymphocytes chemotherapy was different between CRS3-5 and Non-CRS of patients with CRS3-5, CRS1-2, and patients without CRS (p=0.00). There was no significant difference in the number of lymphoblasts after FC deplete lymphocytes chemotherapy, CAR species, and costimulatory molecules. In the multivariate analysis, hematopoietic stem cell transplantation before CAR-T treatment, the numbers of lymphoblasts in the bone marrow before FC deplete lymphocytes chemotherapy, and the CAR species were independent risk factors. For patients with lymphoma, there was no difference in IPI scores, clinical staging, and infused number of CAR-T cells. There were no significant differences in β2-MG, light chain type, myeloma cell number, and ISS stage in patients with MM. Conclusion: The occurrence of CRS in different B-cell tumors has its own characteristics. Compared with ALL and lymphoma, the incidence of severe CRS in MM patients is lower and occurs later. 2. The risk factors of CRS in different B-cell tumors are different. Individualized treatment of is needed in clinical practice. Figure 1 Characteristics of CRS (A. the incidence of CRS, B. days of fever onset after CAR-T infusion, C. duration of fever, D. peak temperature of fever) Figure 1 Disclosures No relevant conflicts of interest to declare.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
cgshao完成签到,获得积分10
刚刚
俏皮的灵完成签到,获得积分10
2秒前
家俊完成签到,获得积分10
3秒前
kk完成签到,获得积分10
5秒前
5秒前
科研通AI6.2的应助被AA采纳,获得10
5秒前
田様的应助被kk采纳,获得10
8秒前
9秒前
9秒前
齐7发布了新的文献求助10
10秒前
spark完成签到,获得积分10
11秒前
chuchu完成签到 ,获得积分10
11秒前
13秒前
14秒前
包语梦发布了新的文献求助10
15秒前
15秒前
齐7完成签到,获得积分10
15秒前
涂豆泥发布了新的文献求助10
20秒前
光亮的成败完成签到,获得积分10
22秒前
傻傻的芷巧完成签到,获得积分10
24秒前
24秒前
28秒前
Yaon-Xu发布了新的文献求助10
29秒前
33秒前
祎辰完成签到 ,获得积分10
36秒前
刘甜甜完成签到,获得积分10
37秒前
顺心鼠标完成签到,获得积分10
39秒前
42秒前
Yaon-Xu发布了新的文献求助10
42秒前
NexusExplorer的应助被李密采纳,获得10
44秒前
庾傀斗发布了新的文献求助10
53秒前
李健的小迷弟的应助被医生采纳,获得10
54秒前
56秒前
58秒前
庾傀斗发布了新的文献求助10
58秒前
Rita发布了新的文献求助10
59秒前
知白发布了新的文献求助10
1分钟前
刻苦的若云完成签到 ,获得积分10
1分钟前
快乐的文博完成签到,获得积分10
1分钟前
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8172940
求助须知:如何正确求助?哪些是违规求助? 9565447
关于积分的说明 21779943
捐赠科研通 7764803
什么是DOI,文献DOI怎么找? 3431480
关于科研通互助平台的介绍 2555495
邀请新用户注册赠送积分活动 2476544